Carl E. Watson
Sandwich, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: December 01, 2025
Prevalence, incidence, and progression of hip osteoarthritis in a young military population: The ADVANCE cohort study.
Journal: Osteoarthritis and cartilage open
Published: June 06, 2025
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 20, 2023
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 05, 2023
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: March 08, 2022
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Journal: Journal for immunotherapy of cancer
Published: September 21, 2020
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
Journal: Science translational medicine
Published: June 22, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 29, 2020
Interactions between clients and outsourced CROs: mind the gap.
Journal: Bioanalysis
Published: August 02, 2017
Recurrence rate of cholesteatoma with autoclaved incus autograft.
Journal: Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Published: September 17, 2014
Measuring soluble biomarkers in clinical trials: do tiered approaches to the analysis and validation of assays provide an answer to the fit-for-purpose challenge?
Journal: Bioanalysis
Published: March 14, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026